Distribution of HLA class II alleles among Scandinavian patients with systemic lupus erythematosus (SLE): an increased risk of SLE among non[DRB1*03,DQA1*0501,DQB1*0201] class II homozygotes?
- PMID: 1440567
- DOI: 10.1111/j.1399-0039.1992.tb02104.x
Distribution of HLA class II alleles among Scandinavian patients with systemic lupus erythematosus (SLE): an increased risk of SLE among non[DRB1*03,DQA1*0501,DQB1*0201] class II homozygotes?
Abstract
HLA-DRB1, -DRB3, -DQA1 and -DQB1 alleles were determined by DNA typing in 51 Scandinavian patients with systemic lupus erythematosus (SLE) and 129 controls. DRB1*03,DRB3*0101,DQA1*0501,DQB1*0201 were significantly increased in the patient group, with relative risks (RR) of 2.80, 3.07, 3.55 and 2.12, respectively. These alleles are in strong linkage disequilibrium, and their possible relative contributions in predisposition to SLE are difficult to distinguish. The strongest association was found for DQA1*0501, which is in linkage disequilibrium with DRB1*03 as well as DRB1*11,12 (DR5). An increased frequency of DRB1*11,12 was observed (RR = 1.89, ns). No association with DRB1*15,16 (DR2) was found. The patients had a higher frequency of HLA class II homozygosity than the controls (RR = 5.05, p = 0.0005). When compared to the low-risk group (nonDRB1*03 class II heterozygotes), the cases homozygous for DRB1*03,DQA1*0501,DQB1*0201, known to be in linkage disequilibrium with the complement allele C4A*Q0, had the highest relative risk of developing SLE (RR = 16.39, p = 0.0002). However non[DRB1*03,DQA1*0501,DQB1*0201] class II homozygotes had a higher relative risk (RR = 4.68, p = 0.0147) than DRB1*03,DQA1*0501,DQB1*0201 heterozygotes, known to carry the C4A*Q0 allele (RR = 2.72, p = 0.0088). This may suggest that HLA class II molecules are directly involved in susceptibility to SLE.
Similar articles
-
Polymorphism of the DQA1 promoter region (QAP) and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. SLE Study Group members.Immunogenetics. 1993;38(6):421-9. doi: 10.1007/BF00184522. Immunogenetics. 1993. PMID: 8406614
-
Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility.Hum Immunol. 2001 Aug;62(8):814-20. doi: 10.1016/s0198-8859(01)00267-1. Hum Immunol. 2001. PMID: 11476905
-
The involvement of HLA -DRB1*, DQA1*, DQB1* and complement C4A loci in diagnosing systemic lupus erythematosus among Tunisians.Ann Saudi Med. 2004 Jan-Feb;24(1):31-5. doi: 10.5144/0256-4947.2004.31. Ann Saudi Med. 2004. PMID: 15310011 Free PMC article.
-
HLA-linked susceptibility and resistance to Takayasu arteritis.Heart Vessels Suppl. 1992;7:73-80. doi: 10.1007/BF01744548. Heart Vessels Suppl. 1992. PMID: 1360976 Review.
-
HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation.Tissue Antigens. 1991 Jul;38(1):1-15. doi: 10.1111/j.1399-0039.1991.tb02029.x. Tissue Antigens. 1991. PMID: 1926129 Review.
Cited by
-
Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus.Clin Dev Immunol. 2012;2012:584374. doi: 10.1155/2012/584374. Epub 2012 Jun 19. Clin Dev Immunol. 2012. PMID: 22761632 Free PMC article. Review.
-
Polymorphism of the DQA1 promoter region (QAP) and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. SLE Study Group members.Immunogenetics. 1993;38(6):421-9. doi: 10.1007/BF00184522. Immunogenetics. 1993. PMID: 8406614
-
HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis.J Clin Invest. 1997 Nov 1;100(9):2227-34. doi: 10.1172/JCI119760. J Clin Invest. 1997. PMID: 9410900 Free PMC article.
-
Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis.Ann Rheum Dis. 2006 Jun;65(6):775-80. doi: 10.1136/ard.2005.041103. Epub 2005 Oct 25. Ann Rheum Dis. 2006. PMID: 16249228 Free PMC article.
-
HLA class II homozygosity confers susceptibility to common variable immunodeficiency (CVID).Clin Exp Immunol. 1999 Jun;116(3):516-20. doi: 10.1046/j.1365-2249.1999.00926.x. Clin Exp Immunol. 1999. PMID: 10361244 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous